Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
CYTOKINETICS, INC. (CYTK) Form 144 notice reports a proposed sale of 6,695 common shares valued at $360,793.55, to be sold through Morgan Stanley Smith Barney on 09/30/2025 on NASDAQ. The shares were acquired as restricted stock units on 10/01/2021 from the issuer and payment was recorded as N/A. The filing also discloses recent 10b5-1 sales by the reported person: 6,756 shares sold on 09/02/2025 for $337,800.00. The filer affirms no undisclosed material adverse information and references Rule 10b5-1 trading plan requirements.
Malik Fady Ibraham, EVP Research & Development at Cytokinetics (CYTK), reported transactions on 09/23/2025. He exercised 2,000 stock options at an exercise price of $10.60 (non-qualified options exercisable since 03/28/2017, expiring 02/28/2027) and acquired 2,000 shares. He simultaneously sold 2,000 shares at $49.28, leaving him with 140,610 shares beneficially owned. The filing was signed by an attorney-in-fact and the box indicating a 10b5-1 plan was checked.
Cytokinetics, Inc. filed an 8-K reporting an Indenture dated September 19, 2025 with U.S. Bank Trust Company, N.A. as trustee that governs the company's 1.75% Convertible Senior Notes due 2031. The filing describes events that would constitute defaults under the Indenture, including failures to pay principal or interest, failures to send required notices, breaches of certain covenants (including on mergers or asset transfers), failures to effect conversions within five business days, uncured defaults under other obligations, specified defaults by significant subsidiaries on indebtedness of at least $50,000,000, and bankruptcy or insolvency events. The filing includes the form of the Note (Exhibit A), press releases dated September 16, 2025, and an interactive cover page XBRL file. The document is signed by Sung H. Lee, Executive VP and CFO.
Cytokinetics states that its New Drug Application for aficamten in obstructive hypertrophic cardiomyopathy is under ongoing regulatory review, and that timing of any approval, final labeling, and the need for a REMS program or other limitations remain uncertain. The company highlights that such regulatory outcomes could affect the commercial prospects for aficamten and could also influence its ability to draw funds under an existing Loan Agreement if conditions are not met. The filing reiterates these are forward-looking statements that speak only as of the report date and that the company may not update them except as required by law.
Dr. Malik Fady Ibraham, EVP Research & Development of Cytokinetics Inc. (CYTK), reported transactions dated 09/09/2025 under a Rule 10b5-1 plan. He exercised 2,000 non‑qualified stock options at a $10.60 exercise price and acquired 2,000 shares, and concurrently sold 2,000 shares at $51.29. After these transactions he beneficially owns 140,610 shares.
Cytokinetics, Incorporated filed an amended current report to correct a missing hyperlink to a press release about new data for its drug candidate aficamten. The press release covers additional aficamten results presented at the European Society of Cardiology Congress 2025 in Madrid.
The data include a pre-specified analysis from the MAPLE-HCM study on how aficamten affects heart structure and function, published in the Journal of the American College of Cardiology, and a Late Breaking Clinical Science presentation on atrial fibrillation incidence and impact associated with aficamten, published in Heart Rhythm.
Cytokinetics, Incorporated filed a report to highlight a key clinical milestone. The company announced that the primary results from its MAPLE-HCM study, which compares metoprolol with aficamten in patients with left ventricular outflow tract (LVOT) obstruction and hypertrophic cardiomyopathy (HCM), were presented in a Hot Line Session at the European Society of Cardiology Congress 2025 in Madrid, Spain. At the same time, these results were published in The New England Journal of Medicine, underscoring the scientific importance of the data. A full press release describing this announcement is included as Exhibit 99.1, giving more detail on the study and its findings.
Dr. Edward M. Kaye, a director of Cytokinetics Inc. (CYTK), reported a sale of 6,756 shares of the issuer's common stock on 09/02/2025 at a reported price of $50 per share, leaving him with 23,230 shares beneficially owned following the transaction. The Form 4 was filed by one reporting person and signed by an attorney-in-fact.
Cytokinetics, Inc. (CYTK) filed a Form 144 notifying a proposed sale of 4,300 common shares, estimated at an aggregate market value of $151,919.00, to be executed approximately on 09/02/2025 on NASDAQ. The securities were acquired as restricted stock units (RSUs) on 01/02/2024 and the filing indicates the broker handling the transaction is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY. The filing states there were 119,657,156 shares outstanding for the class reported. No securities of the issuer were reported sold by the reporting person in the prior three months. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Insider sale reported: Director Robert A. Harrington sold 2,150 shares of Cytokinetics, Inc. (CYTK) on 09/02/2025 at $48.67 per share, reducing his direct holdings to 20,493 shares. The Form 4 indicates the sale was reported under a transaction code for a sale and the filing was signed by an attorney-in-fact. The form also marks a box indicating the transaction may have been made pursuant to a written plan.